Company / R&D Expense
Axsome Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$183.3M
FY2025
5-year range
$57.9M / $187.1M
FY2021-FY2025
Trend
-2.0%
vs FY2024
Sector context
#88 of 210
Health Care
What the data says
At $183M, Axsome Therapeutics, Inc.'s r&d expense ranks #88 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $20M in FY2017 to $187M in FY2024.
Based on SEC 10-K filings.
$183M in FY2025 with a 5-year CAGR of +21.1%.
Improved from $98M to $183M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +46.8%
- 5-Year CAGR
- +21.1%
- 10-Year CAGR
- -
Sector benchmark
#88 of 210 in Health CareTop 42% of 210This company $183.3M Sector average $644.1M
▼
-71.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.1%, indicating consistent growth.
- In FY2025, r&d expense decreased 2.0% year-over-year.
- Ranks #88 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $183.3M | -2.0% |
| FY2024 | $187.1M | +91.0% |
| FY2023 | $97.9M | +69.0% |
| FY2022 | $57.9M | -0.2% |
| FY2021 | $58.1M | -17.3% |
| FY2020 | $70.2M | +30.9% |
| FY2019 | $53.6M | +128.3% |
| FY2018 | $23.5M | +17.7% |
| FY2017 | $20.0M | -5.9% |
| FY2016 | $21.2M | +212.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026